B. Sullenger

发表

B. Sullenger, E. Gilboa, Bruce A. Sullenger, 2002, Nature.

The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa

B. Sullenger, A. Krishnan, E. Vogler, 2012, Journal of Thrombosis and Thrombolysis.

Optimizing aptamer activity for gene therapy applications using expression cassette SELEX.

J. Nevins, B. Sullenger, R. Martell, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Crystal structure of an RNA aptamer bound to thrombin.

B. Sullenger, S. Long, M. Long, 2008, RNA.

Nucleic acid-binding polymers as anti-inflammatory agents

B. Sullenger, D. Pisetsky, K. Leong, 2011, Proceedings of the National Academy of Sciences.

Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

Yong Wang, Eli Gilboa, J. McNamara, 2006, Nature Biotechnology.

RNA aptamers as reversible antagonists of coagulation factor IXa

B. Sullenger, T. Ortel, C. Rusconi, 2002, Nature.

Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer.

B. Sullenger, S. Nair, D. Boczkowski, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis.

B. Sullenger, A. Kirk, E. Elster, 2017, Biomaterials.

RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

B. Sullenger, P. Kuo, Yingmiao Liu, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.

B. Sullenger, P. Ray, Rebekah R White, 2013, Nucleic acid therapeutics.

A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function

B. Sullenger, Rebekah R White, K. Viles, 2008, Angiogenesis.

Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts.

B. Sullenger, C. Gersbach, Jaewoo Lee, 2016, Biochemical and biophysical research communications.

Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen‐specific T‐cell responses

B. Sullenger, Jaewoo Lee, S. Nair, 2008, Immunology.

Ribozyme-mediated repair of defective mRNA by targeted trans-splicing

T. Cech, B. Sullenger, Bruce A. Sullenger, 1994, Nature.

Nucleic Acid Scavenging Polymers Inhibit Extracellular DNA-Mediated Innate Immune Activation without Inhibiting Anti-Viral Responses

B. Sullenger, E. Ramsburg, G. Pitoc, 2013, PloS one.

Aptamers: an emerging class of therapeutics.

B. Sullenger, S. Nimjee, C. Rusconi, 2005, Annual review of medicine.

Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass

B. Sullenger, S. Stayrook, R. Camire, 2018, Nature Biotechnology.

Targeting DAMPs with Nucleic Acid Scavengers to Treat Lupus.

B. Sullenger, R. Rempel, Lyra B Olson, 2022, Translational research : the journal of laboratory and clinical medicine.

Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.

B. Sullenger, L. Que, Ruwan Gunaratne, 2022, Nucleic acid therapeutics.

Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.

B. Sullenger, J. Zweier, R. Becker, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker.

B. Sullenger, P. Ray, Rebekah R White, 2012, The Journal of clinical investigation.

Target Sites in Human Cells Group II Introns Designed to Insert into Therapeutically Relevant DNA

B. Sullenger, A. Lambowitz, M. Long, 2013 .

Trans-splicing reactions by ribozymes.

B. Sullenger, J. T. Jones, S. W. Lee, 1997, Methods in molecular biology.

Histone Deacetylase 7 Inhibition in A Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury.

D. Corcoran, B. Sullenger, D. Remick, 2020, Shock.

Antidote‐Controlled Antithrombotic Therapy Targeting Factor IXa and Von Willebrand Factor

B. Sullenger, R. Becker, S. Oney, 2009, Annals of the New York Academy of Sciences.

In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9

B. Sullenger, D. Hsu, P. Ray, 2016, Molecular therapy. Nucleic acids.

The Nucleic Acid Scavenger Polyamidoamine Third-Generation Dendrimer Inhibits Fibroblast Activation and Granulation Tissue Contraction

B. Sullenger, M. Selim, H. Levinson, 2014, Plastic and reconstructive surgery.

RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit + Cardiac Progenitor Cells

B. Sullenger, S. Nair, C. Milano, 2015 .

Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury.

B. Sullenger, S. Gnyawali, C. Sen, 2018, Journal of visualized experiments : JoVE.

The many faces of the contact pathway and their role in thrombosis

B. Sullenger, R. Becker, R. Woodruff, 2011, Journal of Thrombosis and Thrombolysis.

Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival.

J. McNamara, B. Sullenger, P. Giangrande, 2005, Biochemical and biophysical research communications.

NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis.

B. Sullenger, B. Clary, Yingmiao Liu, 2007, Biochemical and biophysical research communications.

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

B. Sullenger, R. Becker, T. Povsic, 2010, Thrombosis and Haemostasis.

83. Cell_Type Specific Delivery of siRNAs with Aptamer_siRNA Chimeras

J. McNamara, B. Sullenger, E. Gilboa, 2006 .

Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin.

B. Sullenger, S. Long, S. Nimjee, 2009, RNA.

Targeted Disruption of β-Arrestin 2-Mediated Signaling Pathways by Aptamer Chimeras Leads to Inhibition of Leukemic Cell Growth

B. Sullenger, Margie Li, M. Fereshteh, 2014, PloS one.

Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study

B. Sullenger, L. Que, R. Bachelder, 2022 .

Differential Transcriptomic Profiling Between Patients With Sepsis-Induced Ards And Sepsis Without Ards

D. Corcoran, B. Sullenger, M. Eikermann, 2021 .

RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin.

M. Dewhirst, B. Sullenger, P. Giangrande, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.

B. Sullenger, R. Juliano, X. Ming, 2012, Nucleic acid therapeutics.

Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.

B. Sullenger, Y. Fortenberry, S. Brandal, 2011, Nucleic acid therapeutics.

Enhancing cardiac reprogramming via synthetic RNA oligonucleotides

B. Sullenger, C. Hodgkinson, Jaewoo Lee, 2020, Molecular therapy. Nucleic acids.

Nucleic acid-binding polymers as anti-inflammatory agents: reducing the danger of nuclear attack

B. Sullenger, D. Pisetsky, K. Leong, 2012, Expert review of clinical immunology.

Histone Deacetylase 3 Associates with Key Regulators of NFkB Signaling in Human Lung Epithelial Cells under Stimulation with LPS

B. Sullenger, E. Soderblom, S. Agarwal, 2020, Journal of the American College of Surgeons.

Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs.

B. Sullenger, Jaewoo Lee, Li Xu, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Notch signaling in cancer stem cells.

B. Sullenger, J. Rich, Jialiang Wang, 2012, Advances in experimental medicine and biology.

2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors.

B. Sullenger, Johannes H. Urban, Jaewoo Lee, 2016, Nucleic acid therapeutics.

Antithrombotic Therapy in Acute Coronary Syndrome: How Far Up the Coagulation Cascade Will We Go?

B. Sullenger, R. Becker, B. Woodruff, 2010, Current cardiology reports.

Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.

B. Sullenger, R. Becker, S. Nimjee, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

An in vitro system for efficiently evaluating gene therapy approaches to hemoglobinopathies

B. Sullenger, C. Smith, R. Howrey, 2000, Gene Therapy.

Age and Comorbidities Predict COVID-19 Outcome, Regardless of Innate Immune Response Severity: A Single Institutional Cohort Study

B. Sullenger, A. Kirk, L. Que, 2022, Critical care explorations.

Developing aptamers into therapeutics.

B. Sullenger, C. Rusconi, B A Sullenger, 2000, The Journal of clinical investigation.

Potent Anticoagulant Aptamer Directed against Factor IXa Blocks Macromolecular Substrate Interaction*

B. Sullenger, D. Monroe, Bruce Sullenger, 2012, The Journal of Biological Chemistry.

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.

B. Sullenger, J. Keys, S. Nimjee, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Rapid test to assess the escape of SARS-CoV-2 variants of concern

Cameron R. Wolfe, B. Sullenger, A. Chilkoti, 2021, Science advances.

Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test

C. Woods, B. Sullenger, B. Kraft, 2021, Science Advances.

Multiplexed, quantitative serological profiling of COVID-19 from a drop of blood by a point-of-care test

C. Woods, B. Sullenger, B. Kraft, 2020, medRxiv.

Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.

B. Sullenger, M. Hershfield, J. Layzer, 2019, Cell chemical biology.

From the RNA world to the clinic

B. Sullenger, S. Nair, 2016, Science.

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Jeffrey M. Sailstad, B. Sullenger, T. Povsic, 2015, The Journal of allergy and clinical immunology.

Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication

T. Lee, B. Sullenger, E. Gilboa, 1990, Molecular and cellular biology.

Alternative approaches for the application of ribozymes as gene therapies for retroviral infections.

B. Sullenger, T. Campbell, 1995, Advances in pharmacology.

Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.

B. Sullenger, A. Ellington, P. Ray, 2012, Nucleic acid therapeutics.

AIDS and HIV infection.

B. Sullenger, C. Smith, Bruce A. Sullenger, 1995, Molecular and cell biology of human diseases series.

Aptamers and siRNAs in Cardiovascular Disease

B. Sullenger, S. Nimjee, S. Oney, 2008 .

Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication

Eli Gilboa, B. Sullenger, E. Gilboa, 1990, Cell.

RNA aptamer therapy for vaso-occlusion in sickle cell disease.

B. Sullenger, M. Telen, R. Zennadi, 2011, Nucleic acid therapeutics.

In vivo activity of nuclease-resistant siRNAs.

Anton P. McCaffrey, Anton P McCaffrey, B. Sullenger, 2004, RNA.

Notch Promotes Radioresistance of Glioma Stem Cells

B. Sullenger, Xiao-Fan Wang, J. Rich, 2009, Stem cells.

Riboswitches--to kill or save the messenger.

B. Sullenger, 2004, The New England journal of medicine.

Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.

B. Sullenger, Seong-Wook Lee, K. Shin, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Retargeting mobile group II introns to repair mutant genes.

John P. Jones, B. Sullenger, A. Lambowitz, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Group II introns designed to insert into therapeutically relevant DNA target sites in human cells.

B. Sullenger, A. Lambowitz, M. Long, 2000, Science.

DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists

B. Sullenger, L. Que, Jaewoo Lee, 2022, Biomaterials.

Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA.

T. Cech, B. Sullenger, 1993, Science.

Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation

B. Sullenger, E. Gilboa, H. Gallardo, 1991, Journal of virology.

Efficient and specific repair of sickle β-globin RNA by trans-splicing ribozymes

B. Sullenger, M. Long, J. Byun, 2003 .

The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides

B. Sullenger, Leaf Huang, R. Juliano, 2010, Journal of drug targeting.

Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking

W. Wetsel, B. Sullenger, Yingmiao Liu, 2009, Journal of neurochemistry.

Aptamers in immunotherapy.

B. Sullenger, S. Nair, Bruce A Sullenger, 2008, Human gene therapy.

Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes

B. Sullenger, S. W. Lee, 1996, The Journal of experimental medicine.

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

J. McNamara, B. Sullenger, E. Gilboa, 2008, The Journal of clinical investigation.

Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector.

B. Sullenger, E. Gilboa, G. Ungers, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.

T. Lee, B. Sullenger, E. Gilboa, 1992, The New biologist.

RNA repair: a novel approach to gene therapy.

B. Sullenger, T. Watanabe, 2000, Advanced drug delivery reviews.

Aptamers as Therapeutics.

B. Sullenger, R. Becker, S. Nimjee, 2017, Annual review of pharmacology and toxicology.

Ribozyme-Mediated Repair of Sickle β-Globin mRNAs in Erythrocyte Precursors

B. Sullenger, Seong-Wook Lee, Clayton A. Smith, 1998 .

Generation of species cross-reactive aptamers using "toggle" SELEX.

B. Sullenger, A. Wolberg, C. Rusconi, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.

B. Sullenger, Michael D Nichols, Bethany Powell Gray, 2019, Cell chemical biology.

A kallikrein‐targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release

B. Sullenger, J. Layzer, K-A Steen Burrell, 2017, Journal of thrombosis and haemostasis : JTH.

Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects

B. Sullenger, R. Rempel, S. Nair, 2021, Molecular therapy. Nucleic acids.

Inhibiting the intrinsic pathway of coagulation with a factor XII–targeting RNA aptamer

B. Sullenger, J. Layzer, W. Wu, 2013, Journal of thrombosis and haemostasis : JTH.

Proximity-dependent and proximity-independent trans-splicing in mammalian cells.

B. Sullenger, K. Viles, 2008, RNA.

Gene therapy progress and prospects: RNA aptamers

B. Sullenger, N. Que-Gewirth, 2007, Gene Therapy.

Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing

B. Sullenger, Bruce A. Sullenger, 2003 .

Conformationally Selective RNA Aptamers Allosterically Modulate the β2-Adrenoceptor

Ryan T. Strachan, B. Sullenger, R. Lefkowitz, 2016, Nature chemical biology.

In vivo selection of tumor-targeting RNA motifs

B. Sullenger, Johannes H. Urban, B. Clary, 2009, Nature chemical biology.

Development of universal antidotes to control aptamer activity

Mark E. Davis, B. Sullenger, J. Heidel, 2009, Nature Medicine.

Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection.

B. Sullenger, J. Layzer, 2007, Oligonucleotides.

Translation and Clinical Development of Antithrombotic Aptamers.

B. Sullenger, R. Becker, T. Povsic, 2016, Nucleic acid therapeutics.

Generation and characterization of aptamers targeting factor XIa.

B. Sullenger, I. Verhamme, R. Woodruff, 2017, Thrombosis research.

Identiﬁcation and Characterization of an Agonistic Aptamer Against the T Cell Costimulatory Receptor, OX40

B. Sullenger, S. Nair, Elizabeth D. Pratico, 2022 .

Antidote-mediated control of an anticoagulant aptamer in vivo

George Quick, B. Sullenger, S. Nimjee, 2004, Nature Biotechnology.

In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells.

B. Sullenger, Seong-Wook Lee, In-Hoo Kim, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.

B. Sullenger, E. Gilboa, S. Nair, 2003, Cancer research.

Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA.

B. Sullenger, C. Smith, S. W. Lee, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.

B. Sullenger, T. Watanabe, Bruce A. Sullenger, 2000, Proceedings of the National Academy of Sciences of the United States of America.

RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.

M. Dewhirst, B. Sullenger, P. Giangrande, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

RGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic

B. Sullenger, 2020, Cell.

Nucleic acid scavengers inhibit thrombosis without increasing bleeding

B. Sullenger, K. Leong, Jaewoo Lee, 2012, Proceedings of the National Academy of Sciences.

Design of therapeutic biomaterials to control inflammation

B. Sullenger, R. Haag, Jaewoo Lee, 2022, Nature Reviews Materials.

Scavenging nucleic acid debris to combat autoimmunity and infectious disease

B. Sullenger, E. Holl, L. Borst, 2016, Proceedings of the National Academy of Sciences.

Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis.

B. Sullenger, D. Pisetsky, Jaewoo Lee, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Polycationic Nanofibers for Nucleic Acid Scavenging.

B. Sullenger, K. Leong, H. Levinson, 2016, Biomacromolecules.

Targeted inhibition of αvβ3 integrin with an RNA aptamer impairs endothelial cell growth and survival

James O McNamara, Paloma H. Giangrande, J. McNamara, 2005 .

Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2

Siqing Shan, Mark W Dewhirst, M. Dewhirst, 2003, Proceedings of the National Academy of Sciences of the United States of America.

IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages

B. Sullenger, S. Agarwal, Brent A. Stanfield, 2021, PloS one.

Multivalent 4-1 BB binding aptamers costimulate CD 8 + T cells and inhibit tumor growth in mice

J. McNamara, B. Sullenger, E. Gilboa, 2007 .

Using 5'-PTMs to repair mutant beta-globin transcripts.

B. Sullenger, M. Kierlin-Duncan, 2007, RNA.

Using 59-PTMs to repair mutant b-globin transcripts

B. Sullenger, M. Kierlin-Duncan, 2007 .

Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO

B. Sullenger, M. Kuchibhatla, D. Bonadonna, 2021, Molecular Therapy. Nucleic Acids.

An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase*

B. Sullenger, C. Rusconi, J. Layzer, 2009, The Journal of Biological Chemistry.

Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist

B. Sullenger, A. Jadhav, S. Nimjee, 2020, Journal of NeuroInterventional Surgery.

Nucleic-Acid Scavengers Mitigate Breast Cancer Induced Inflammation, Invasion, and Metastasis

B. Sullenger, R. Rempel, S. Nair, 2020 .

Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.

Mark W Dewhirst, M. Dewhirst, B. Sullenger, 2008, The Journal of surgical research.

Applications and future of aptamers that achieve rapid-onset anticoagulation

B. Sullenger, Haixiang Yu, J. Frederiksen, 2023, RNA.

Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.

B. Sullenger, M. Long, J. Byun, 2003, RNA.

The Inhibition of Anti-DNA Binding to DNA by Nucleic Acid Binding Polymers

B. Sullenger, D. Pisetsky, K. Leong, 2012, PloS one.

A high affinity, antidote‐controllable prothrombin and thrombin‐binding RNA aptamer inhibits thrombin generation and thrombin activity

B. Sullenger, D. Monroe, F. Church, 2012, Journal of thrombosis and haemostasis : JTH.

Toll-like receptor activation as a biomarker in traumatically injured patients.

B. Sullenger, A. Kirk, E. Elster, 2018, The Journal of surgical research.

Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies

B. Sullenger, Seong-Wook Lee, 1997, Nature Biotechnology.

Antimetastatic potential of PAI-1-specific RNA aptamers.

B. Sullenger, D. Lawrence, Y. Fortenberry, 2009, Oligonucleotides.

Rapid molecular imaging of active thrombi in vivo using aptamer-antidote probes

B. Sullenger, R. Rempel, S. Nimjee, 2023, Molecular therapy. Nucleic acids.

Therapeutic Aptamers: Evolving to Find Their Clinical Niche.

B. Sullenger, S. Nimjee, 2020, Current medicinal chemistry.

Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.

B. Sullenger, R. Becker, D. Ginsburg, 2007, Oligonucleotides.

RNA aptamer to thrombin binds anion‐binding exosite‐2 and alters protease inhibition by heparin‐binding serpins

B. Sullenger, C. Rusconi, F. Church, 2004, FEBS letters.

Aptamer-programmable adeno-associated viral vectors as a novel platform for cell-specific gene transfer

B. Sullenger, M. Kay, Chuanling Zhang, 2023, Molecular therapy. Nucleic acids.

Something old, something new.

B. Sullenger, F. Steele, 2011, Nucleic acid therapeutics.

PEG‐Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response

B. Sullenger, A. Chilkoti, A. Hucknall, 2022, Advanced materials.

NF-κB inhibition by an adenovirus expressed aptamer sensitizes TNFα-induced apoptosis

B. Sullenger, B. Clary, Yingmiao Liu, 2007 .

Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.

B. Sullenger, E. Gilboa, Jaewoo Lee, 2008, Chemistry & biology.

Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.

B. Sullenger, K. Bompiani, E. Soule, 2016, Nucleic acid therapeutics.

A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling.

Yong Wang, Eli Gilboa, B. Sullenger, 2009, Macromolecular bioscience.

Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia

J. Nevins, B. Sullenger, P. Giangrande, 2007, Proceedings of the National Academy of Sciences.

Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function

B. Sullenger, 2000 .

Gene Therapy Applications of Ribozymes

John P. Jones, B. Sullenger, L. Milich, 2003 .

Mixed-surface polyamidoamine polymer variants retain nucleic acid-scavenger ability with reduced toxicity

B. Sullenger, D. Pisetsky, A. Chilkoti, 2022, iScience.

β-Cyclodextrin-containing Polymer Treatment of Cutaneous Lupus and Influenza Improves Outcomes.

Mark E. Davis, B. Sullenger, J. Everitt, 2021, Molecular Therapy.

Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis

D. Bigner, B. Sullenger, B. Clary, 2009, Biological chemistry.

A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.

B. Sullenger, D. Laskowitz, Haichen Wang, 2011, Oligonucleotides.

Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa

B. Sullenger, H. Lyerly, C. Rusconi, 2000, Thrombosis and Haemostasis.

Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples

B. Sullenger, Haixiang Yu, E. Soule, 2022, Cell Chemical Biology.

Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures.

B. Sullenger, T. LaBean, K. Gothelf, 2012, Nanomedicine : nanotechnology, biology, and medicine.

Nucleic acid aptamers in therapeutic anticoagulation

B. Sullenger, R. Becker, C. Rusconi, 2005, Thrombosis and Haemostasis.

Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function

J. Nevins, B. Sullenger, J. Ishizaki, 1996, Nature Medicine.

Histone Deacetylase 7 In Murine Gram-Negative Acute Lung Injury.

D. Corcoran, B. Sullenger, D. Remick, 2020, Shock.

Key Pathogenic Factors in Coronavirus Disease 2019–Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report

B. Sullenger, B. Kraft, L. Que, 2021, A&A practice.

Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors.

B. Sullenger, C. Smith, S. W. Lee, 1998, Science.

Emerging applications of aptamers for anticoagulation and hemostasis

B. Sullenger, Ruwan Gunaratne, C. V. Chabata, 2018, Current opinion in hematology.

Modulation of the Coagulation Cascade Using Aptamers

B. Sullenger, R. Woodruff, 2015, Arteriosclerosis, thrombosis, and vascular biology.

Woodruff and Sullenger Modulation of the Coagulation Cascade Using Aptamers 2085

B. Sullenger, R. Woodruff, 2022 .

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

B. Sullenger, R. Becker, T. Povsic, 2010, Journal of cardiovascular translational research.

Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor.

J. Doudna, T. Cech, B. Sullenger, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Tunable cytotoxic aptamer–drug conjugates for the treatment of prostate cancer

B. Sullenger, M. Levy, A. Barry, 2018, Proceedings of the National Academy of Sciences.

Regulatable aptamers in medicine: focus on antithrombotic strategies

B. Sullenger, A. Potti, T. Ortel, 2004, Expert opinion on biological therapy.

An Aptamer That Rapidly Internalizes into Cancer Cells Utilizes the Transferrin Receptor Pathway

B. Sullenger, Haixiang Yu, Bethany Powell Gray, 2023, Cancers.

Emerging clinical applications of nucleic acids

B. Sullenger, 2000 .

Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms

B. Sullenger, S. Nair, D. Boczkowski, 2023, Frontiers in immunology.

An Aptamer for Broad Cancer Targeting and Therapy

B. Sullenger, M. Levy, D. Hsu, 2020, Cancers.

Targeted genetic repair: an emerging approach to genetic therapy.

B. Sullenger, 2003, The Journal of clinical investigation.

Optimizing the substrate specificity of a group I intron ribozyme.

P. Zarrinkar, B. Sullenger, 1999, Biochemistry.

Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.

B. Sullenger, G. Pitoc, G. Mackensen, 2014, Chemistry and Biology.

Colocalizing ribozymes with substrate rnas to increase their efficacy as gene inhibitors

B. Sullenger, 1995, Applied biochemistry and biotechnology.

Utilizing directed evolution to interrogate and optimize CRISPR/Cas guide RNA scaffolds.

J. Gorodkin, B. Sullenger, J. Layzer, 2023, Cell chemical biology.

H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity

B. Sullenger, B. Clary, Ž. Vujašković, 2006, Nucleic acids research.

The potential of aptamers as anticoagulants.

B. Sullenger, R. Harrington, S. Nimjee, 2005, Trends in cardiovascular medicine.

Functional repair of a mutant chloride channel using a trans-splicing ribozyme.

B. Sullenger, C. Rogers, C. Vanoye, 2002, The Journal of clinical investigation.

Applications and future of aptamers that achieve rapid-onset anticoagulation

B. Sullenger, Haixiang Yu, J. Frederiksen, 2023, RNA.

A high affinity, antidote‐controllable prothrombin and thrombin‐binding RNA aptamer inhibits thrombin generation and thrombin activity

B. Sullenger, D. Monroe, K. Bompiani, 2012, Journal of thrombosis and haemostasis : JTH.

Modulation of the Coagulation Cascade Using Aptamers

B. Sullenger, R. Woodruff, 2015, Arteriosclerosis, thrombosis, and vascular biology.

Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis.

B. Sullenger, D. Pisetsky, Jaewoo Lee, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Notch Promotes Radioresistance of Glioma Stem Cells

B. Sullenger, Xiao-Fan Wang, J. Rich, 2009, Stem cells.

Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs.

B. Sullenger, Jaewoo Lee, Li Xu, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Emerging clinical applications of RNA

B. Sullenger, E. Gilboa, 2002, Nature.

Tagging ribozyme reaction sites to follow trans–splicing in mammalian cells

Joshua T. Jones, B. Sullenger, Seong-Wook Lee, 1996, Nature Medicine.

Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study

B. Sullenger, L. Que, R. Bachelder, 2022, Anesthesiology.

Scavenging nucleic acid debris to combat autoimmunity and infectious disease

B. Sullenger, E. Ramsburg, E. Holl, 2016, Proceedings of the National Academy of Sciences.

Revising messages traveling along the cellular information superhighway.

B. Sullenger, 1995, Chemistry & biology.

Utilizing directed evolution to interrogate and optimize CRISPR/Cas guide RNA scaffolds.

J. Gorodkin, B. Sullenger, J. Layzer, 2023, Cell chemical biology.

RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit(+) Cardiac Progenitor Cells.

B. Sullenger, B. Feger, Elizabeth D. Pratico, 2015, Stem cells and development.

Evaluating and enhancing ribozyme reaction efficiency in mammalian cells

Joshua T. Jones, B. Sullenger, 1997, Nature Biotechnology.